Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CATXBullishResearch Analysisnews

High materiality7/10

William Blair Starts CATX Coverage With Outperform on Radiopharma Growth

Sep 18, 2026, 2:15 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Analyst initiation with an Outperform rating and a clear price target well above current levels can catalyze short- to medium-term upside, particularly if radiopharma sector momentum sustains and CATX progresses toward milestones.

AI summary

What happened, with direct paths to the underlying reporting

William Blair initiated coverage on Perspective Therapeutics (CATX) with an Outperform rating, citing lead-212 radiopharmaceuticals and a robust peptide platform. The report notes a potential U.S. radiopharmaceutical market up to $35B and a de-risked pathway as manufacturing and regulatory dynamics improve. A fair-value of about $11.45 per share suggests meaningful upside if milestones are met.

William Blair initiates CATX coverage with Outperform rating.
Perspective leverages lead-212 radiopharmaceuticals and a peptide platform.
Radiopharmaceutical market opportunity cited at up to $35B in the U.S.
Fair value estimated at $11.45/ share vs ~$2.70 current price; 13% discount rate.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.